Document Detail


Oral labetalol in the management of stable angina pectoris in normotensive patients.
MedLine Citation:
PMID:  3917674     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The efficacy of labetalol, an alpha and beta receptor antagonist, was evaluated in 12 normotensive patients with stable angina pectoris in a single blind dose ranging study. After a two week period of placebo treatment, labetalol was given in doses of 100, 150, 200, and 300 mg twice daily, each for two weeks. Frequency of angina attacks decreased from 9.4 (SEM 2.3)/week in the control period to 7.3 (2.8), 5.2 (2.6), 3.8 (1.8), and 3.3 (1.9)/week in the four successive treatment periods. In the same periods the number of glyceryl trinitrate tablets consumed decreased from 7.0 (2.6)/week to 5.8 (3.3), 3.9 (2.9), 2.7 (1.8), and 2.6 (2.1)/week. Maximal symptom limited treadmill exercise tests were performed three and 12 hours after dosage at each dose. Exercise tolerance (expressed as seconds of the Bruce protocol) increased from 266 (44) with placebo to 306 (44), 369 (50), 396 (48), and 413 (51) in the four treatment periods. This improvement was accompanied by a significant blunting of the heart rate and blood pressure responses to exercise. Trough point exercise tolerance did not differ significantly from that at three hours after dosage. Thus labetalol is effective as an antianginal agent at doses of 150-300 mg twice daily and is well tolerated by the normotensive patient with angina.
Authors:
J W Upward; F Akhras; G Jackson
Related Documents :
17196454 - Gender comparison of efficacy and safety of ranolazine for chronic angina pectoris in f...
17931784 - Evaluation of the efficacy and safety of a novel formulation of metaflumizone in cats n...
352634 - The effect of lidoflazine on exercise tolerance in patients with angina pectoris.
3938114 - Isosorbide-5-mononitrate--effective monotherapy in chronic stable angina.
7282554 - Two dimensional echocardiographic evaluation of exercise-induced left and right ventric...
22301834 - Altering endogenous carbohydrate availability to support training adaptations.
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  British heart journal     Volume:  53     ISSN:  0007-0769     ISO Abbreviation:  Br Heart J     Publication Date:  1985 Jan 
Date Detail:
Created Date:  1985-03-05     Completed Date:  1985-03-05     Revised Date:  2009-11-18    
Medline Journal Info:
Nlm Unique ID:  0370634     Medline TA:  Br Heart J     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  53-7     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Angina Pectoris / drug therapy*,  physiopathology
Blood Pressure / drug effects
Clinical Trials as Topic
Dose-Response Relationship, Drug
Drug Therapy, Combination
Ethanolamines / therapeutic use*
Exercise Test
Female
Heart Rate / drug effects
Humans
Labetalol / administration & dosage,  adverse effects,  therapeutic use*
Male
Middle Aged
Nitroglycerin / therapeutic use
Chemical
Reg. No./Substance:
0/Ethanolamines; 36894-69-6/Labetalol; 55-63-0/Nitroglycerin
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Characterization of T cells bearing HLA-DR antigens in rheumatoid arthritis.
Next Document:  Studies on interleukin 2 receptor expression and IL-2 production by murine T cell lymphomas.